CLNN
Clene Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.10
+8.75%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$3.93
From 52W high−62.45%
Volume114935.00
Market cap$57.68M
P/E (TTM)—
P/S (TTM)292.8x
Div yield—
Key dataNov 4, 2026
Open
$3.93
From 52W high
−62.45%
Volume
114935.00
Market cap
$57.68M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.5x
P/E (TTM)
—
RSI (14)
51.8
MomentumView details →
1D Return
+8.75%
YTD Return
−33.73%
SummaryUpdated Jun 1, 2026
Clene Inc. (NASDAQ:CLNN) is a clinical-stage pharmaceutical company founded in 2013 and headquartered in Salt Lake City, Utah. The company went public in October 2018 and focuses on developing novel nanotechnology-based therapeutics for treating neurodegenerative diseases. Clene specializes in clean-surfaced nanotechnology (CSN) therapeutics, with its lead drug candidate CNM-Au8 currently in multiple clinical trials for conditions including amyotrophic lateral sclerosis (ALS), multiple sclerosis, and Parkinson's disease. The company operates in the biotechnology sector within the broader healthcare industry.
Similar companies
Latest newsMore news →
Clene Inc. reported quarterly earnings of $0.05 per share, compared with a loss of $0.85 per share a year earlier.9h agoClene Inc. announced its third-quarter 2026 financial results and operating highlights.11h agoClene Inc. submitted a New Drug Application to the U.S. Food and Drug Administration seeking accelerated approval of CNM-Au8 for amyotrophic lateral sclerosis.17d ago